This website uses cookies to enhance the user experience.
S

SIFOTEK AS927 631 539

Research
Limited company
Fabrikkveien 8 4033 STAVANGER, Norge

SIFOTEK AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
3 years
since Sep 1, 2021
Type
Limited company
VAT registered
Yes
Number of employees
5

Ownership

Number of shares and share classes
2,000,000
1 share class
Total number of shareholders
3
2 companies, 1 person
Belongs to group of

Financials

Total operating income 2023
1,427,300
NOK
Annual total result 2023
-2,826,991
NOK
Total equity 2023
4,313,142
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO
93 %
indirectly

Board

NameRoleShares
Chairman
93 %
indirectly
Board Member-

Others

NameRoleShares
J
JM ØKONOMIPARTNER AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Managing Director/CEO, Chairman
93 %
indirectly
-
2 %
indirectly
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classNumber of sharesShare
S
SKYTEK HOLDING AS
Ordinary shares
1,860,000
93 %
Ordinary shares
100,000
5 %
A
AURAK AS
Ordinary shares
40,000
2 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 3,206,100
    Operating profit 2023: NOK 3,119,271
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
1,427,300
401,300
0
Annual Total Result
-2,826,991
-1,093,959
-167,888
Total assets
6,604,698
11,185,915
884,554
Total liabilities
2,291,555
2,236,601
852,442
Total equity
4,313,142
8,949,314
32,112

P&L

Year202320222021
Total operating income
1,427,300
401,300
0
Total operating costs
4,421,686
1,893,279
167,888
Operating result
-2,994,386
-1,491,979
-167,888
Financial income/costs
167,395
0
0
Profit before tax
-2,826,991
-1,491,979
-167,888
Total tax & extraordinary income/cost
0
-398,020
0
Annual Total Result
-2,826,991
-1,093,959
-167,888

Balance overview

Year202320222021
Total fixed assets
0
0
0
Total current assets
6,604,698
11,185,915
884,554
Total assets
6,604,698
11,185,915
884,554
Short term debt
491,555
436,601
52,442
Long term debt
1,800,000
1,800,000
800,000
Total liabilities
2,291,555
2,236,601
852,442
Contributed capital
4,313,142
8,949,314
200,000
Retained earnings
0
0
-167,888
Total equity
4,313,142
8,949,314
32,112
Total equity and liabilities
6,604,698
11,185,915
884,554

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology